Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BONESUPPORT HOLDING AB ( (SE:BONEX) ) is now available.
BONESUPPORT HOLDING AB announced positive results from a clinical study demonstrating the effectiveness of CERAMENT® G in managing periprosthetic joint infections (PJI) of the hip. Conducted at Charité – Universitätsmedizin Berlin, the study showed no infection recurrence in patients over a 24-month follow-up period, highlighting significant improvements in patient-reported outcomes. This advancement positions CERAMENT G as a promising solution for single-stage revision surgeries, potentially impacting the standard of care in orthopedic surgery by reducing the risk of reinfection compared to the traditional two-stage procedure.
The most recent analyst rating on (SE:BONEX) stock is a Buy with a SEK346.00 price target. To see the full list of analyst forecasts on BONESUPPORT HOLDING AB stock, see the SE:BONEX Stock Forecast page.
More about BONESUPPORT HOLDING AB
BONESUPPORT HOLDING AB is a leading company in the orthobiologics industry, specializing in the development and commercialization of innovative injectable bio-ceramic bone graft substitutes. These products are designed to remodel into the patient’s own bone and have the capability of eluting drugs. The company is based in Lund, Sweden, and reported net sales of SEK 899 million in 2024.
Average Trading Volume: 141,391
Technical Sentiment Signal: Buy
Current Market Cap: SEK19.49B
Learn more about BONEX stock on TipRanks’ Stock Analysis page.